News

A study suggests that a novel CAR T-cell therapy could be a curative treatment for some patients with chronic lymphocytic leukemia, with 25% of responders still in remission after 6 years.

The FDA has approved the combination of osimertinib plus chemotherapy for the treatment of EGFR-mutated non-small cell lung cancer.

The FDA has approved lifileucel, a tumor infiltrating lymphocyte therapy, for the treatment of advanced melanoma.

Michiel S. Van der Heijden, MD, PhD, discusses the methods, design, and findings of the phase 3 CheckMate 901 trial of concurrent frontline nivolumab and chemotherapy followed by nivolumab maintenance therapy in urothelial carcinoma.

In an interview with Targeted Oncology, Douglas Tremblay, MD, discussed the significance of cytoreductive therapy in mitigating thrombotic risk in myeloproliferative neoplasms.

Pedro Barata, MD, MSc, FACP, discusses tackling unmet needs in oncology at the NRG Oncology Semiannual Meeting taking place February 15-17, 2024.

Following the FDA clearance of an investigational new drug application, a phase 1 trial will evaluate KME-0584 for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.

The FDA has granted an orphan drug designation to tigilanol tiglate for the treatment of soft tissue sarcoma.

In an interview with Targeted Oncology, Stephen J. Schuster, MD, further discussed the rationale and findings from the phase 2 ELARA study of tisa-cel among patients with follicular lymphoma.

The FDA has now fully approved tepotinib for the treatment of metastatic non-small cell lung cancer.

A phase 2 trial is underway to assess alisertib for extensive-stage small cell lung cancer treatment, aiming to enroll up to 60 patients.

In an interview with Targeted Oncology, Eric Schroeder, MD, discussed the transformative shift that the landscape of ovarian cancer treatment has undergone in recent years.

In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.

In an interview for Cholangiocarcinoma Awareness Day, Domenech Asbun, MD, discussed how the management of cholangiocarcinoma continues to evolve and addressed unmet needs in early detection and systemic therapy.

Paula Rodriguez-Otero, MD, PhD, provides an overview of the phase 3 KarMMa-3 trial of idecabtagene vicleucel for the treatment of adult patients with relapsed and refractory multiple myeloma.

Neal Shore, MD, FACS, discusses a study aimed to investigate the real-world survival outcomes of men with metastatic castration-sensitive prostate cancer treated with either apalutamide or enzalutamide in the United States.

In an interview with Targeted Oncology, Shervin Tabrizi, MD, discussed the development of a 2-part priming strategy aimed at enhancing the sensitivity of liquid biopsies for cancer detection and monitoring.

A phase 1, first-in-human study is evaluating a novel CAR T-cell therapy in patients with ovarian cancer at Moffitt Cancer Center.

The biologics license application for denileukin diftitox has been resubmitted to the FDA for the treatment of cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The FDA has granted the supplemental new drug application of repotrectinib priority review.

A phase 2 trial for the treatment of gastric, esophageal, and gastroesophageal junction cancer is evaluating agenT-797 with botensilimab, balstilimab, ramucirumab, and paclitaxel.

Raajit K. Rampal, MD, PhD, discusses some of the key takeaways from the 2023 American Society of Hematology Annual Meeting and what he believes holds promise for the space in 2024.

Liposomal irinotecan with 5-fluorouracil, leucovorin, and oxaliplatin (NALIRIFOX) is now an FDA-approved treatment option for patients with metastatic pancreatic ductal adenocarcinoma.

A trial investigating REM-001 therapy in cutaneous metastatic breast cancer has been initiated.

In an interview, Ira Zackon, MD, emphasized the need for community-based, inclusive care, and the importance of utilizing technology to address disparities in the modern era of chronic lymphocytic leukemia treatment.

The FDA has granted fast track designation to BXCL701 with an immune checkpoint inhibitor for metastatic small cell neuroendocrine prostate cancer resistant to chemotherapy and showing no evidence of microsatellite instability.

Eric Schroeder, MD, discusses how treatments for patients with ovarian cancer have evolved in recent years.

In an interview with Targeted Oncology, Clara Hwang, MD, discussed the notable differences in molecular alterations observed in the retrospective cohort study among Black men with metastatic castration-resistant prostate cancer compared with White men.

There are currently no FDA-approved agents for relapsed peripheral T-cell lymphoma, and soquelitinib has the potential to fill an unmet need.

The phase 1 study of HEMO-CAR-T in patients with acute myeloid leukemia can proceed following the lifted clinical hold.